QQ客服 官方微博 反馈留言

浏览/检索结果: 共3条，第1-3条 帮助 已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 ALK-G1269A mutation in epithelioid inflammatory myofibroblastic sarcoma after progression on crizotinib: A case report 期刊论文 ONCOLOGY LETTERS, 2019, 卷号: 17, 期号: 2 作者:  Xu, Xiaojing;  Li, Hong;  Peng, Ke;  Yu, Yiyi;  Chen, Lingli 收藏  |  浏览/下载：22/0  |  提交时间：2019/12/05 epithelioid inflammatory myofibroblastic sarcoma  anaplastic lymphoma kinase  kinase inhibitor  crizotinib  Brigatinib  drug resistance   Design, synthesis and pharmacological evaluation of ALK and Hsp90 dual inhibitors bearing resorcinol and 2,4-diaminopyrimidine motifs 期刊论文 EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 卷号: 152, 页码: 76-86 作者:  Geng, Kaijun;  Liu, Hongchun;  Song, Zilan;  Zhang, Chi;  Zhang, Minmin 收藏  |  浏览/下载：179/0  |  提交时间：2019/01/08 Heat shock protein 90 (Hsp90)  Tyrosine kinase ALK  Dual inhibitor  Drug resistance  Antiproliferative activity   Discovery of 2,4-diarylaminopyrimidines bearing a resorcinol motif as novel ALK inhibitors to overcome the G1202R resistant mutation 期刊论文 EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 卷号: 144, 页码: 386-397 作者:  Geng, Kaijun;  Xia, Zongjun;  Ji, Yinchun;  Zhang, Ruisi (Ruthy);  Sun, Deqiao 收藏  |  浏览/下载：156/0  |  提交时间：2019/01/08 ALK  G1202R mutant  Drug resistance  2,4-Diarylaminopyrimidine  Resorcinol